Phase IIb study of milciclib in combination with the standard of care treatment sorafenib in patients with hepatocellular carcinoma
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2019
Price : $35 *
At a glance
- Drugs Milciclib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Apr 2019 According to a Tiziana Life Sciences media release, the company Expects to initiate a Phase 2b trial (TZLS (201)-125a-011) dosing Milciclib in combination with Sorafenib in patients with HCC in 2019.
- 14 Dec 2017 Planned initiation date changed to 1 Apr 2018.
- 11 Dec 2017 According to a Tiziana Life Sciences media release, this trial is expected to begin in in Q2, 2018.